A Novel Heterozygous Deletion Variant in KLOTHO Gene Leading to Haploinsufficiency and Impairment of Fibroblast Growth Factor 23 Signaling Pathway

• Published in: Journal of clinical medicine Vol. 8; no. 4; p. 500
• Main Authors: Martín-Núñez, Ernesto, Donate-Correa, Javier, Kannengiesser, Caroline, De Brauwere, David-Paul, Leroy, Christine, Oudin, Claire, Friedlander, Gérard, Prieto-Morín, Carol, Tagua, Víctor G., Ureña-Torres, Pablo A., Navarro-González, Juan F.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 12.04.2019
• Subjects: haploinsufficiency; Klotho; end-stage renal disease; deletion; hyperphosphatemia; fibroblast growth factor 23
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm8040500

Hyperphosphatemia is commonly present in end-stage renal disease. Klotho (KL) is implicated in phosphate homeostasis since it acts as obligate co-receptor for the fibroblast growth factor 23 (FGF23), a major phosphaturic hormone. We hypothesized that genetic variation in the KL gene might be associated with alterations in phosphate homeostasis resulting in hyperphosphatemia. We performed sequencing for determining KL gene variants in a group of resistant hyperphosphatemic dialysis patients. In a 67-year-old female, blood DNA sequencing revealed a heterozygous deletion of a T at position 1041 (c.1041delT) in exon 2. This variation caused a frameshift with substitution of isoleucine for phenylalanine and introduction of a premature termination codon (p.Ile348Phefs*28). cDNA sequencing showed absence of deletion-carrier transcripts in peripheral blood mononuclear cells suggesting degradation of these through a nonsense-mediated RNA decay pathway. Experiments in vitro showed that p.Ile348Phefs*28 variant impaired FGF23 signaling pathway, indicating a functional inactivation of the gene. In the patient, serum levels of KL were 2.9-fold lower than the mean level of a group of matched dialysis subjects, suggesting a compromise in the circulating protein concentration due to haploinsufficiency. These findings provide a new loss-of-function variant in the human KL gene, suggesting that genetic determinants might be associated to clinical resistant hyperphosphatemia.